PRESS RELEASE: Exploiting the oncogenic drivers of the CCNG1 pathway

DeltaRex-G generates significant interest in a Commentary published in Molecular Therapy Family of Journals, the Official Organ of the American Society of Gene and Cell Therapy (ASGCT).